ArticleBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy2026
Biological Medicines, Biosimilars and Their Automatic Substitution: Concerns, Knowledge and Information Needs of People with Diabetes.
Article in BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAutomatic substitution of biological medicines was introduced in Finnish community pharmacies in 2024, including glargine insulins in 2025. Patient views on this policy have mainly been studied with other patients than people with diabetes (PwD). Unlike other biological medicines, insulin has a narrow therapeutic window, carries risk of hypoglycemia and hyperglycemia, and requires patient-directed dose adjustments. Therefore, it is essential to explore the views of PwD regarding automatic substitution.
objectivesTo investigate the concerns of insulin-treated PwD regarding the automatic substitution of insulins, their knowledge and information needs related to biological medicines, biosimilars, and automatic substitution, and the factors associated with this knowledge.
methodsAn electronic survey was conducted in May 2024. Chi-squared test and binary logistic regression were used to examine the association between participant characteristics and outcome variables.
resultsAmong the 459 participants, 62% expressed concerns about whether the substituted insulin would be as good as the insulin previously used and about the expertise of pharmacists (47%) and physicians (46%). Awareness of biological medicines (67%) exceeded awareness of automatic substitution (45%) and biosimilars (38%), although 63% correctly identified the definition of a biosimilar. Inferior knowledge was associated with higher HbA1c, fewer comorbidities, shorter long-acting insulin use, male gender, age over 70, and use of long-acting insulin as part of multiple daily injections. Over half (55%) reported needing more information.
conclusionsAwareness of biosimilars and automatic substitution of biological medicines was limited among PwD. These findings underscore the importance of targeted communication and education to ensure medically safe substitutions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.